Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Nkarta has initiated an investigator-sponsored trial of NKX019, a CD19-directed chimeric antigen receptor NK-cell therapy for systemic lupus erythematosus. Additionally, in June 2024, Nkarta initiated the NTRUST-1 Phase 1 trial of NKX019 for lupus nephritis.
July 24, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nkarta has initiated trials for NKX019, targeting systemic lupus erythematosus and lupus nephritis. These developments could potentially lead to significant advancements in CAR NK-cell therapy.
The initiation of trials for NKX019 indicates progress in Nkarta's pipeline, which could lead to future revenue streams if the trials are successful. This is likely to have a positive short-term impact on the stock price as investors react to the potential for new treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100